Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study.

Urologic oncology·2017
Same author

Diagnostic Accuracy of <sup>64</sup>Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.

Urology·2017
Same author

The Microbiome of the Prostate Tumor Microenvironment.

European urology·2017
Same author

Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study.

Urologic oncology·2017
Same author

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer.

Clinical genitourinary cancer·2017
Same author

Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.

European urology·2017
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
Same journal

Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

European urology·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus

Silke Gillessen1, Fabio Turco2, Ian D Davis3

  • 1Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland.

European Urology
|October 11, 2024
PubMed
Summary
This summary is machine-generated.

The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on clinical management questions. Voting results address areas lacking high-level evidence, guiding physicians and research priorities.

Keywords:
Adjuvant therapyBiochemical recurrenceBone protectionGenetics and genomicsHormonal treatmentNext-generation imagingPositron emission tomographyProstate cancerProstate-specific membrane antigenSalvage therapy

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.6K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.8K

Related Experiment Videos

Last Updated: Jun 10, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.6K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.8K

Area of Science:

  • Oncology
  • Urology
  • Clinical Practice Guidelines

Background:

  • Despite innovations, advanced prostate cancer (PC) management lacks high-level evidence in key areas.
  • Daily clinical practice is significantly impacted by these evidence gaps.

Purpose of the Study:

  • To survey international experts on critical clinical management questions for advanced prostate cancer.
  • To supplement existing evidence-based guidelines with expert consensus findings.
  • To identify areas of consensus and non-consensus for future research prioritization.

Main Methods:

  • A modified Delphi process was used by 120 international PC experts to develop 183 consensus questions.
  • Questions covered eight distinct topics relevant to advanced prostate cancer management.
  • A web-based survey administered questions to the expert voting panel prior to the conference.

Main Results:

  • Voting results demonstrated varying degrees of expert agreement on management questions.
  • Consensus was defined as ≥75% agreement, with strong consensus at ≥90% agreement.
  • The study identified specific areas of non-consensus requiring further investigation.

Conclusions:

  • Findings aid clinicians and patients in navigating evidence-scarce or conflicting areas of advanced PC management.
  • Results inform funders and policymakers on research priorities for prostate cancer.
  • Individualized treatment decisions, clinical trial enrollment, and addressing identified research gaps are emphasized.